BCL2 and acute myeloid leukemia: Small molecule inhibitors such as FLT3 inhibitors, IDH inhibitors, and BCL-2 inhibitor as a single agent or in combination with other therapies are new to the arsenal of AML therapy (Rashidi et al., 2018).